Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologics vs MMF Induction Therapy in Proliferative Lupus Nephritis
NCT07340463Phase 2Recruiting
- Sponsor
- Nanjing University School of Medicine
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of belimumab, telitacicept in lupus nephritis (LN), systemic lupus erythematosus (SLE), sponsored by Nanjing University School of Medicine. Started Dec 2025; status: recruiting.
02
Drugs
belimumabtelitacicept
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07340463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340463.